Details for Patent: 6,589,552
Summary for Patent: 6,589,552
| Title: | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The invention provides fenofibrate compositions comprising granulates. The granulates can comprise micronized fenofibrate, inert hydrosoluble carrier particles, hydrophilic polymers, and, optionally, surfactants. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | André Stamm, Pawan Seth | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Laboratories Fournier SAS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US10/126,875 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Process; Dosage form; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 6,589,552: Fenofibrate Formulation Claims, Expiration, and Patent LandscapeUS Patent 6,589,552 protects a multiparticulate fenofibrate formulation using micronized fenofibrate, water-soluble carrier particles, and a substantial amount of hydrophilic polymer. The strongest claim scope centers on the combination of:
The patent issued in 2003 and its ordinary US patent term has expired. It therefore does not create a current US blocking right, although its claims remain relevant for historical product reconstruction, freedom-to-operate analysis, patent prosecution strategy, and interpretation of related fenofibrate patent families. What does US Patent 6,589,552 protect?The patent protects pharmaceutical compositions rather than fenofibrate as a chemical entity. Its claims target an oral delivery system designed to improve dissolution and absorption of poorly water-soluble fenofibrate. The core formulation requires a granulated composition containing:
The independent claims are claims 1, 31 and 57. Claim 1 is the broadest independent composition claim. Claim 31 narrows the polymer to polyvinylpyrrolidone and expressly requires a surfactant. Claim 57 requires a hydrophilic polymer and at least one surfactant, with a surfactant-to-polymer ratio of 1:500 to 1:10. The patent does not claim all micronized fenofibrate products. A product must satisfy the required formulation architecture and quantitative limitations. How many independent claims does US 6,589,552 have?The patent has three principal independent composition claims:
Claims 2-30 depend from claim 1. Claims 32-55 depend from claim 31. Claim 56 depends from claim 1 and clarifies that the hydrophilic polymer can be a mixture. The claim set is therefore structured as three overlapping formulation layers:
What technical problem does the patent address?Fenofibrate has low aqueous solubility. Micronization reduces particle size and increases surface area, but micronization alone does not necessarily provide adequate dissolution or consistent bioavailability. The claimed formulation addresses this problem through several coordinated elements:
The specification’s formulation theory is reflected in the claim structure. The patent does not rely solely on particle size. It requires particle size in combination with polymer loading, carrier selection, and, in several claims, surfactant content or dissolution behavior. What formulations are protected by claims 1 through 30?Claims 1 through 30 cover a broad family of granulated fenofibrate products. Fenofibrate particle-size limitationsClaim 1 requires fenofibrate below 20 microns. Claim 2 narrows that limitation to below 10 microns. The phrase “below 20 μm” is a numerical limitation. A formulation using fenofibrate with a measured particle-size distribution above that threshold may fall outside the claim, depending on the applicable measurement method and whether the claim requires the entire population or a specified distribution parameter. The claims as provided do not state whether the limitation applies to D90, mean diameter, median diameter, or another particle-size metric. That issue would matter in an infringement dispute. Fenofibrate concentrationThe dependent claims provide the following active-content ranges:
A formulation with 30% fenofibrate falls within both dependent ranges if all parent-claim elements are present. The ranges do not replace the broader claim 1 limitation. They add narrower concentration requirements. Hydrophilic-polymer contentThe polymer limitations are:
The polymer is a central claim element. A product using a low level of polymer, or using a non-hydrophilic excipient that does not meet the claim construction, presents a potentially meaningful design-around route. Fenofibrate-to-polymer ratioClaim 1 requires a weight ratio from 1:10 to 4:1. Claim 8 narrows the range to 1:2 to 2:1. At a 1:1 ratio, a composition falls within both the broad and narrow ratio ranges, assuming the other limitations are satisfied. The ratio is calculated by weight, not by molar amount or volume. Polymer identityClaim 9 lists:
Claim 10 narrows the polymer to polyvinylpyrrolidone. Claim 56 expressly covers mixtures of hydrophilic polymers. The Markush structure creates broad chemical coverage, but it also limits the claims to the listed polymers or legally equivalent materials. An alternative polymer not within the listed group could avoid the literal scope of claims 9 and 10, while still potentially implicating claim 1 if it qualifies as a hydrophilic polymer. What carrier particles are protected?The carrier particles must be inert and hydrosoluble. The listed materials are:
Claims 11 and 12 specify carrier-particle loading:
Claims 13 and 14 specify carrier-particle size:
Claims 15 and 16 narrow the carrier to the listed materials and lactose, respectively. A formulation using a non-water-soluble carrier, a carrier outside the claimed particle-size range, or a carrier not falling within the applicable claim language may avoid particular dependent claims. Claim 1, however, does not itself recite the specific 50-500 micron range or a particular carrier chemistry. What surfactant formulations are protected?Claims 17 through 26 add surfactant limitations to the claim 1 family. The listed surfactants include sodium lauryl sulfate, polysorbates, sodium dioctylsulfosuccinate, lecithin, fatty alcohols, cholesterol, polyoxyethylene derivatives and poloxamers. The principal quantitative limitations are:
Claim 19 narrows the surfactant to sodium lauryl sulfate. Claim 26 requires co-micronization of fenofibrate and surfactant. Claim 31 is particularly important because it combines:
A product using PVP and sodium lauryl sulfate may therefore fall within several overlapping claim paths. What dissolution performance is required?Claims 24, 25, 49 and 50 require the following dissolution profile:
The test uses a rotating blade at 75 rpm under the cited European Pharmacopoeia method. Two dissolution media are specified:
These are product-performance limitations, not merely formulation-composition limitations. A product can contain the same excipients as the claimed formulation but fall outside claims 24, 25, 49 or 50 if it does not meet the required dissolution thresholds under the specified testing conditions. The dissolution claims also raise evidentiary issues. Testing would need to address:
Do claims 29 and 30 cover manufacturing methods?Claims 29 and 30 are dependent composition claims that characterize the granules by the manufacturing process used to make them. Claim 29 requires spraying a suspension containing fenofibrate and hydrophilic polymer onto inert hydrosoluble carrier particles. Claim 30 narrows the process to fluidized-bed granulation. These are product-by-process limitations within composition claims, rather than standalone process claims. Their practical scope depends on claim construction. In an infringement analysis, the relevant question would be whether the accused product has the claimed composition and whether the process language limits the claim to products made by the specified method. The manufacturing limitations create potential design-around opportunities. A product formed by dry granulation, roller compaction, direct compression, solvent evaporation, spray drying or another process may present a noninfringement argument under a narrow interpretation of the process language. That argument would depend on the prosecution history and applicable Federal Circuit precedent. When did US Patent 6,589,552 expire?US Patent 6,589,552 was issued on July 8, 2003. Its US term was based on the application’s effective filing and priority dates and expired in approximately 2017, subject to any patent-term adjustment, terminal disclaimer or other recorded term event. The patent is no longer an enforceable US patent right. The expiry means:
The precise expiration date should be taken from the USPTO Patent Center term-adjustment and maintenance records for the patent. Public patent databases generally identify the patent as expired by the late 2010s. What was the FDA and Orange Book relevance?The patent concerns an oral fenofibrate formulation, a product category associated with Tricor and later fenofibrate products. FDA approval and Orange Book listing are separate from patent validity and enforceability. A patent can be:
US 6,589,552 should not be treated as a current Orange Book barrier solely because it covers a fenofibrate formulation. Orange Book status must be confirmed through the FDA’s current Approved Drug Products with Therapeutic Equivalence Evaluations database and the relevant reference-listed drug entry. The patent’s expiration independently removes its current blocking effect. Fenofibrate products have also been approved through different regulatory routes and dosage forms, including tablets, capsules and combination products. The relevant patent certifications depend on the specific reference-listed drug and dosage form. Which companies challenged fenofibrate exclusivity?Fenofibrate faced generic competition from multiple manufacturers after FDA approval of abbreviated new drug applications. Companies active in the US fenofibrate market have included Teva, Mylan, Impax, Sandoz, Watson/Actavis and other generic manufacturers, depending on product strength and dosage form. The major historical patent disputes involving branded fenofibrate products generally focused on patents covering formulation, bioavailability, dosage forms and product-specific delivery characteristics. They did not necessarily involve US 6,589,552 as the only asserted patent. A Paragraph IV certification against a fenofibrate patent would require the ANDA applicant to allege that the patent is invalid, unenforceable or not infringed. The patent’s expiration means that any historical Paragraph IV significance has ended as a current launch barrier. How strong was the patent estate?Claim-strength assessment
The strongest historical protection was the combination of micronized fenofibrate, high hydrophilic-polymer loading and water-soluble carrier particles. The claim set is less powerful against formulations using a different manufacturing route, a different polymer system, no carrier particles, or a substantially different polymer-to-drug ratio. The patent did not claim:
It claimed specific combinations of those components and performance characteristics. How does US 6,589,552 compare with other fenofibrate patents?The fenofibrate patent landscape has generally divided into five categories:
US 6,589,552 falls in the formulation and manufacturing interface. It is narrower than a compound patent but potentially more relevant to a specific commercial product than a general fenofibrate compound disclosure. Related fenofibrate patents, including patents associated with Fournier and later branded-product owners, should be reviewed as a family rather than in isolation. Patent numbers frequently cited in the historical Tricor landscape include US 6,074,670 and US 6,277,405, but their claim scope, term, listing status and litigation history must be analyzed separately from US 6,589,552. What generic launch risks existed?Before expiration, a generic fenofibrate product could face risk if it replicated the claimed combination of:
Potential design-around paths included:
Because the patent has expired, these historical strategies no longer create a current US launch requirement. What geographic coverage does the patent have?US 6,589,552 provides US-only rights. It does not directly protect products in Europe, Canada, Japan, China or other jurisdictions. The underlying invention may have been pursued through corresponding foreign applications and regional patent families. Foreign counterparts can have:
A global freedom-to-operate review therefore requires separate analysis of the corresponding European, Canadian, Australian and other national patents. Expiration of the US patent does not establish expiration of every foreign counterpart. Key Takeaways
FAQsIs US 6,589,552 a patent on Tricor?It is a fenofibrate formulation patent associated with the technical field used by branded fenofibrate products, but the patent does not claim the Tricor brand name or every Tricor formulation. Does using micronized fenofibrate infringe US 6,589,552?Micronization alone is insufficient. The relevant claim also requires the specified polymer, carrier particles, quantitative ratios and other limitations. Does lactose automatically create infringement risk?No. Lactose is a claimed carrier in dependent claims, but lactose alone does not satisfy the full claim combination. Is a formulation with polyvinylpyrrolidone covered?It may be, if it also contains the required micronized fenofibrate, hydrosoluble carrier particles, polymer concentration, drug-to-polymer ratio and, for claim 31, a surfactant. Can US 6,589,552 block a new generic fenofibrate launch?No. The US patent has expired. A current launch analysis must identify unexpired patents, FDA exclusivity, applicable Orange Book listings and any separate regulatory barriers. References
More… ↓ |
Drugs Protected by US Patent 6,589,552
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,589,552
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| France | 97 00479 | Jan 17, 1997 |
International Family Members for US Patent 6,589,552
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 011411 | ⤷ Start Trial | |||
| Austria | 233556 | ⤷ Start Trial | |||
| Austria | 291911 | ⤷ Start Trial | |||
| Austria | 307576 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
